RAPT Therapeutics, Inc. (NASDAQ:RAPT) Shares Sold by Jane Street Group LLC

Jane Street Group LLC lessened its holdings in shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) by 66.9% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 66,515 shares of the company’s stock after selling 134,498 shares during the quarter. Jane Street Group LLC owned 0.19% of RAPT Therapeutics worth $134,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of RAPT. Point72 Asset Management L.P. grew its stake in RAPT Therapeutics by 176,725.0% during the 2nd quarter. Point72 Asset Management L.P. now owns 707,300 shares of the company’s stock valued at $2,157,000 after purchasing an additional 706,900 shares in the last quarter. Federated Hermes Inc. grew its stake in RAPT Therapeutics by 188.7% during the 2nd quarter. Federated Hermes Inc. now owns 796,080 shares of the company’s stock valued at $2,428,000 after purchasing an additional 520,368 shares in the last quarter. Acadian Asset Management LLC grew its stake in RAPT Therapeutics by 4,183.3% during the 2nd quarter. Acadian Asset Management LLC now owns 467,182 shares of the company’s stock valued at $1,424,000 after purchasing an additional 456,275 shares in the last quarter. Cubist Systematic Strategies LLC grew its stake in RAPT Therapeutics by 826.4% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 295,241 shares of the company’s stock valued at $900,000 after purchasing an additional 263,372 shares in the last quarter. Finally, Los Angeles Capital Management LLC grew its stake in RAPT Therapeutics by 138.1% during the 3rd quarter. Los Angeles Capital Management LLC now owns 201,439 shares of the company’s stock valued at $405,000 after purchasing an additional 116,853 shares in the last quarter. Institutional investors and hedge funds own 99.09% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on RAPT shares. JPMorgan Chase & Co. lowered RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a research note on Monday, November 11th. Piper Sandler lowered RAPT Therapeutics from an “overweight” rating to a “neutral” rating and decreased their target price for the stock from $8.00 to $2.00 in a research report on Monday, November 11th. HC Wainwright upgraded RAPT Therapeutics from a “neutral” rating to a “buy” rating and set a $10.00 target price for the company in a research report on Thursday, December 26th. Stifel Nicolaus reiterated a “hold” rating and issued a $2.00 target price (down previously from $7.00) on shares of RAPT Therapeutics in a research report on Wednesday, November 13th. Finally, Wells Fargo & Company decreased their target price on RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating for the company in a research report on Tuesday, November 12th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and three have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $9.56.

RAPT Therapeutics Trading Down 8.3 %

Shares of NASDAQ RAPT opened at $1.21 on Tuesday. The company has a market cap of $42.30 million, a price-to-earnings ratio of -0.44 and a beta of 0.07. RAPT Therapeutics, Inc. has a 12-month low of $0.79 and a 12-month high of $27.35. The stock’s 50 day simple moving average is $1.41 and its 200 day simple moving average is $2.03.

RAPT Therapeutics (NASDAQ:RAPT) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.09. As a group, equities analysts forecast that RAPT Therapeutics, Inc. will post -2.86 earnings per share for the current fiscal year.

RAPT Therapeutics Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.